The short version of research chemical fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-04-07 and is reviewed periodically as new material appears.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | N-terminal fragment of thymosin beta-4 |
| Residue count | Seven | Sequence LKKTETQ |
| Approximate mass | 889 Da | Acetylated seven-residue peptide |
| Common synonyms | TB4 fragment, TB500 | Not identical to full-length TB4 |
| Reported activity | Actin binding | Observed mainly in cell-free systems |
The most frequently cited identity is a seven-residue fragment with the sequence LKKTETQ, taken from the actin-binding domain of the parent protein. A separate molecule, N-acetyl-seryl-aspartyl-lysyl-proline, often shortened to Ac-SDKP, derives from the same protein's N-terminal region and appears in overlapping literature. Reported molecular masses therefore differ between sources, and a mass value on its own does not establish which fragment is present. Confirmation requires a defined sequence rather than a single number.
Research interest in thymosin beta-4 fragments centres on actin sequestration, cell migration and tissue repair models. Most published work uses cultured cells or animal wound and cardiac preparations, and findings are generally described as preliminary. No fragment of this protein has been approved as a therapeutic product by major regulators. Reviews of the field note inconsistent dosing, delivery routes and outcome measures across studies, which complicates direct comparison. The material is best understood as a laboratory reagent with an active but unresolved research literature.
Sports authorities classify the peptide as a prohibited substance, and it appears on the World Anti-Doping Agency list under peptide hormones, growth factors, and related substances. Racing jurisdictions for horses and dogs have issued separate restrictions, and several national bodies treat it as a controlled or prescription-only item. As a research chemical it is sold without a therapeutic indication, and labels usually state that the product is not for human or veterinary use. Regulatory treatment therefore varies by country.
Detection in biological matrices generally relies on liquid chromatography coupled with tandem mass spectrometry, because the peptide lacks a convenient ultraviolet chromophore beyond the amide backbone. Immunoassays have been described, but antibodies raised against the fragment can cross-react with the full-length protein or with unrelated peptides, so findings usually require confirmation by a second technique. Sample preparation typically involves protein precipitation followed by solid-phase extraction. Reported detection windows depend on dose, route, matrix, and instrument sensitivity.
Animal work has examined the peptide in models of cardiac injury, skin wounding, and corneal repair, with reported outcomes covering cell migration, inflammatory cell influx, and tissue remodeling. Several of those experiments used the full-length protein or longer fragments instead of the seven-residue sequence, which makes direct comparison between reports difficult. Results are generally described as tissue-dependent, and effect sizes vary considerably across laboratories. Independent replication is uneven, so the overall picture is incomplete rather than settled.
Controlled human trials of the short fragment are scarce. Much of what appears in review articles is extrapolated from animal models or from studies of the parent protein, and literature searches return a larger body of cardiac and ophthalmic work on thymosin beta-4 than on the abbreviated peptide. Regulatory treatment differs by jurisdiction, and in several countries the material is handled as a research chemical rather than an approved therapeutic. Statements about human benefit should be read as provisional.
Lyophilized TB-500 is hygroscopic and should be kept dry before use. The usual storage recommendation for the solid is -20 °C, protected from light and moisture. Once dissolved, the peptide is less stable, and repeated freeze-thaw cycles can promote aggregation or degradation. Laboratories often divide a reconstituted solution into single-use aliquots and store them at -80 °C. Exact stability limits depend on buffer, pH, and concentration, so published data do not define a single universal condition.
Identity and purity are checked with chromatographic and mass spectrometric methods. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities, while mass spectrometry confirms the expected molecular mass. A certificate of analysis may report a purity percentage, but the laboratory should still verify the material independently. Common quality concerns include truncated sequences, deamidation, oxidation, and residual solvents from synthesis. Because TB-500 is short, some impurities can differ from the target by only a few mass units.
=== Muscle spasticity === Botulinum toxin is used to treat a number of disorders characterized by overactive muscle movement, including cerebral palsy, post-stroke spasticity, post-spinal cord injury spasticity, spasms of the head and neck, eyelid, vagina, limbs, jaw, and vocal cords. Similarly, botulinum toxin is used to relax the clenching of muscles, including those of the esophagus, jaw, lower urinary tract and bladder, or clenching of the anus which can exacerbate anal fissure. Botulinum toxin appears to be effective for refractory overactive bladder.
== Function == The function of proton-coupled amino acid transporters is the transmembrane movement of amino acids and their derivatives for absorption by the luminal surface of the small intestine or digestion by intralysosomal proteins. In Drosophila models, the expression of SLC family genes that code for proton-coupled amino acid transporters is directly linked to the nutrient-dependent growth. In humans, similar expression patterns are observed and their function correlates to their location anatomically. Being located within the lamina of the small intestine allows for functional absorption of transported amino acids and derivatives. The majority of nutrient absorption takes place within this region of the intestines, and makes sense that these transporters are located throughout this tissue.
=== Heating === Heating methods are often used to ensure that glass and other lab equipment are free of pyrogenic material. Heat is applied by baking in a dry heat oven that is designed specifically for the depyrogenation process. Although endotoxins are relatively thermally stable, sufficient heating (250 °C for 30 min) results in a 3-log reduction of endotoxin levels. Due to the high temperature levels, this method is also not suitable when purifying proteins.
=== Mark McVeigh Era (2026–present) === On Monday 24th of August 2026, Mark McVeigh was appointed Senior Coach of Essendon, a three year contract running through to the end of the 2029 AFL season. Club President Andrew Welsh said the decision was unanimously supported by the club board, and stating in a press release that "we have been extremely clear on the strategy and direction of this football club. We are building the next successful era for Essendon, with a view to playing finals, winning finals and competing for premierships. Mark is the best coach to take us forward to achieve that."
=== A public-health approach === A common critical view holds that the war on drugs has been costly and ineffective largely because US federal and state governments have chosen the wrong methods, focusing on interdiction and punishment rather than regulation and treatment of drug abuse and addiction. In the US, current public health-oriented interventions include harm reduction, drug courts, and Law Enforcement Assisted Diversion (LEAD) programs which give police treatment or social services options rather than arrest with minor drug offenses. Harm reduction approaches include provision of sterile syringes, medically supervised injection sites (SIF), and availability of the opioid overdose-countering drug naloxone. As an alternative to imprisonment, drug courts in the US identify substance-abusing offenders and place them under strict court monitoring and community supervision, as well as provide them with long-term treatment services. According to a National Drug Court Institute report, 16.4% of the nation's drug court graduates are rearrested and charged with a felony within one year of completing the program; overall 44.1% of released prisoners end up back in prison within one year. The drug court program is also significantly cheaper than imprisonment. Annual per offender cost is $20,000–$50,000 for imprisonment, and $2,500–$4,000 in the drug court system. A survey by the Substance Abuse and Mental Health Services Administration (SAMHSA) found that substance abusers who remain in treatment longer are less likely to resume their former drug habits.
Sources: en.wikipedia.org
In January 2026, the US Food and Drug Administration requested removal of suicidal behavior and ideation warnings from glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications. While adolescents taking GLP-1 drugs experienced more gastrointestinal symptoms, they had a lower risk of acute pancreatitis compared to the control group. A similar study in adults reported similar results for semaglutide. A 2025 study suggested that GLP-1 agonists increased risks of hypotension (low blood pressure), syncope (fainting), joint diseases, nephrolithiasis (kidney stones), interstitial nephritis, and acute pancreatitis.
Essentially, these specialized reticular cells form pathways that guide T cells deeper into cancer tissue, improving immune responses and tumor regulation in the body. The findings suggest that reticular cells, previously thought to be limited to only lymphoid tissues, can reform immune environments within tumors. This opens many new possibilities for cancer treatment in the world of medicine. Moreover, reticular cells help balance immune activation and tolerance. By regulating cytokine and antigen accessibility, they prevent excessive immune responses in cells that could actually damage host tissues. Through these methods, they act as immune regulators, ensuring that the body initiates very strong defenses against pathogens while minimizing potential damage. The emerging evidence recognizes reticular cells as a potential important factor of disease regulation connecting immunity to tissue repair and inflammation control in the body.
=== Sleep === Gabapentin is effective in treating sleep disorders such as insomnia and restless legs syndrome that are the result of an underlying illness, but comes with some risk of discontinuation and withdrawal symptoms after prolonged use at higher doses. Gabapentin enhances slow-wave sleep in people with primary insomnia. It also improves sleep quality by elevating sleep efficiency and decreasing spontaneous arousal.
Banlieue Triste was already attracting attention, wrote Frank Colombani of Le Monde, and the band were therefore courted by the Spinefarm Records label. Spinefarm Records released the album on 28 September 2018 in all territories outside France. A special double-vinyl edition of the album was released simultaneously, following the signing of the quartet Chanut, Thépegnier, Hanvic, and Toufouti to Spinefarm Records, thereby guaranteeing worldwide distribution for their future recordings. Hope /// Dope /// Rope, This Is Not Supposed To Be Positive and Banlieue Triste "are part of a whole", thus constituting a "trilogy", Chanut said. Banlieue Triste led the band to appear on the French television channel Canal+ for a short concert on the programme L'album de la Semaine (lit. 'Album of the Week'), to be broadcast on FIP and France Inter, and to be featured in articles in the general-interest press. While the band frequently toured the Upper France region during the winter of 2018, they opened for Zeal & Ardor at L'Aéronef in Lille and for Samael in Dunkirk. They regularly performed in Belgium and the Netherlands because their manager was based in Lille. The single "Lost Brothel" was released in July 2019, ahead of a four-track EP titled Bus de Nuit (lit. 'Night Bus'). On 16 August 2019, Hangman's Chair performed at the Psycho Las Vegas festival in Nevada, US. A joint performance by Hangman's Chair and the post-black metal band Regarde Les Hommes Tomber (lit.
Sources: en.wikipedia.org
==== Suicides and homicides ==== Tyson Mathews (1983–2013) died in Teralba, New South Wales, Australia, on 7 November 2013 just six days after his 30th birthday. The cause of death was determined to be suicide by hanging. At the time of his death, he was subject to a community treatment order (CTO) mandating depot antipsychotic injections of paliperidone palmitate (brand name Invega Sustenna). The inquest specifically investigated whether this medication was a contributing factor. His mother was concerned about the appropriateness of paliperidone palmitate. She observed that after the dose was increased, her son's psychotic symptoms settled, but he became "markedly more depressed." She questioned whether the drug contributed to his condition and death. Despite his depression (neuroleptic dysphoria) worsening, Ms. Mathews felt healthcare professionals did not fully acknowledge the deterioration. Andrew Jeffrey Rich (1989–2019) was a Wisconsin man placed under court-ordered assisted outpatient treatment (AOT) following a breakdown in May 2017. He was required to receive regular injections of Invega Sustenna under Wisconsin's Chapter 51 commitment law. Over approximately 18 months, recommitment orders were repeatedly extended on the basis that he denied having a mental illness and would likely stop medication if released, despite his psychiatrist acknowledging no observed psychotic symptoms during that period and Rich living and working independently in the community.
=== Celebrex intellectual property settlement (2012) === Brigham Young University (BYU) said a professor of chemistry, Dr. Daniel L. Simmons, discovered an enzyme in the 1990s that led towards development of Celebrex. BYU was originally seeking a 15% royalty on sales, equating to $9.7 billion. A research agreement had been made between BYU and Monsanto, whose pharmaceutical business was later acquired by Pfizer, to develop a better aspirin. The enzyme Dr. Simmons claims to have discovered would induce pain and inflammation while causing gastrointestinal problems and Celebrex is used to reduce those issues. A six-year battle ensued because BYU claimed that Pfizer did not give Dr. Simmons credit or compensation, while Pfizer claimed that it had met all obligations regarding the Monsanto agreement. In May 2012, Pfizer settled the allegations, agreeing to pay $450 million.
Many diagnostic approaches depend on microbiological culture to isolate a pathogen from the appropriate clinical specimen. In a microbial culture, a growth medium is provided for a specific agent. A sample taken from potentially diseased tissue or fluid is then tested for the presence of an infectious agent able to grow within that medium. Many pathogenic bacteria are easily grown on nutrient agar, a form of solid medium that supplies carbohydrates and proteins necessary for growth, along with copious amounts of water. A single bacterium will grow into a visible mound on the surface of the plate called a colony, which may be separated from other colonies or melded together into a "lawn". The size, color, shape and form of a colony is characteristic of the bacterial species, its specific genetic makeup (its strain), and the environment that supports its growth. Other ingredients are often added to the plate to aid in identification. Plates may contain substances that permit the growth of some bacteria and not others, or that change color in response to certain bacteria and not others. Bacteriological plates such as these are commonly used in the clinical identification of infectious bacterium. Microbial culture may also be used in the identification of viruses: the medium, in this case, being cells grown in culture that the virus can infect, and then alter or kill. In the case of viral identification, a region of dead cells results from viral growth, and is called a "plaque". Eukaryotic parasites may also be grown in culture as a means of identifying a particular agent.
=== Electronic effects === Owing to inductive effects, the basicity of an amine might be expected to increase with the number of alkyl groups on the amine. Correlations are complicated owing to the effects of solvation which are opposite the trends for inductive effects. Solvation effects also dominate the basicity of aromatic amines (anilines). For anilines, the lone pair of electrons on nitrogen delocalizes into the ring, resulting in decreased basicity. Substituents on the aromatic ring, and their positions relative to the amino group, also affect basicity as seen in the table.
PREP C20: a column-based preparative fractionation instrument, capable to fractionate up to 20 grams of polymer. Soluble fraction CRYSTEX: instrument intended to measure the amorphous fraction of polypropylene and ethylene-propylene copolymers, for quality control laboratories for polypropylene manufacturing plants. CRYSTEX QC: fully automated instrument for amorphous phase determination in PP/EP manufacturing QC laboratories. CRYSTEX 42: high-throughput system for simultaneous measurement of the soluble fraction, ethylene content and intrinsic viscosity in a fully automated process for up to 42 samples. Infrared detectors
Sources: en.wikipedia.org
No. Thymosin beta-4 is a 43-residue protein, while TB-500 refers to a seven-residue fragment corresponding to its N-terminal region. The two names are often used loosely in commercial and community writing, which obscures the difference in size, sequence, and likely behavior.
The fragment contains an actin-binding motif, and cell-free experiments show that it can interact with monomeric actin. That observation is the basis for interest in cell migration and repair processes. Effects reported in animals are not established for humans.
Purity is usually stated by the supplier rather than fixed by a pharmacopoeial monograph, and typical listings report a percentage from reverse-phase HPLC. Independent verification is uncommon. Because no single accepted specification exists, comparisons between lots and between suppliers are difficult.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.